Santen Inc. USAVice President, Global Alliances & External Research (GAER), Global Ophthalmology R&D,Emeryville, California
Naj Sharif, PhD, DSc, FARVO, FBPhS is a graduate of Southampton University, England (UK) where he received his BSc (Joint Honors: Biochemistry and Physiology), PhD (Neuroscience) and DSc (Ophthalmology by thesis). He has been in the pharmaceutical industry for >33-years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Pfizer (Cambridge, UK), Syntex / Roche (Palo Alto, CA), Alcon-Novartis (Ft. Worth, TX), and is currently at Santen Inc (VP, Ophthalmology R&D; Emeryville, CA).
Dr. Sharif’s 22-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan®, Patanol®, Emedine®, Simbrinza®, Izba® and Pazeo® to treat glaucoma/ocular hypertension and ocular allergies. He served as Board member for Santen on the InnFocus Inc Board of Directors, and was co-responsible for acquiring Innfocus Inc for Santen, and has thus helped add a device for glaucoma treatment to the product pipeline.
Dr. Sharif is an active member of Assoc. Res. Vision & Ophthalmology (ARVO), Int. Soc. Eye Research (ISER), Assoc. Ocular Pharmacology & Therapeutics (AOPT; elected Trustee 2019), Assoc. Soc. Pharmacology & Therapeutics (ASPET) and British Pharmacological Society (BPS), and has actively served on many committees of these societies for multiple years. He was recently elected as a Fellow of ARVO (FARVO; Silver Medal 2014; Gold Medal 2019), and Fellow of BPS (FBPhS, 2017). Dr. Sharif was honored as the first recipient of the inaugural Dr. Roger Vogel award for ocular pharmaceutical research presented by the ARVO Foundation (2014), and the “Sir James Black Award” for contributions to drug discovery from BPS (2017). He serves as Editor and/or on the editorial boards of numerous scientific journals, is an Adjunct Professor and Graduate Faculty / Thesis Advisor for many MS- and PhD-students at several global Universities. He has published >205 scientific articles, co-edited 2 books, and is also the holder of 24 issued US and EU patents. He is currently a Vice President in Global Ophthalmology R&D at Santen Inc (Emeryville, CA), supporting and building Global Alliances with other Pharma companies and academic institutions, and is actively participating in and supporting collaborative eye disease and therapeutics discovery research. Such exemplary leadership has led to Dr. Sharif being recently named as an Honorary Senior Principal Investigators at the Singapore Eye Research Institute (SERI), and as an Honorary Senior Lecturer at the Imperial College of Science & Technology (University of London).